WO2004087043A2 - Stable ophthalmic formulation containing an antibiotic and a corticosteroid - Google Patents
Stable ophthalmic formulation containing an antibiotic and a corticosteroid Download PDFInfo
- Publication number
- WO2004087043A2 WO2004087043A2 PCT/IN2004/000048 IN2004000048W WO2004087043A2 WO 2004087043 A2 WO2004087043 A2 WO 2004087043A2 IN 2004000048 W IN2004000048 W IN 2004000048W WO 2004087043 A2 WO2004087043 A2 WO 2004087043A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- cyclodextrin
- agent
- amount ranging
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Definitions
- the present invention relates to a stable ophthalmic composition comprising an anti- infective agent and an anti-inflammatory agent.
- Formulations containing an anti-infective agent and an anti-inflammatory agent such as corticosteroid are useful for topical application to the eye, ear, nose or skin.
- Corticosteroids are insoluble in water and thus are generally available in suspended form or are dissolved in oil or solvents when used in the formulation.
- oil or solvents it would be desirable to avoid the use of oil or solvents and provide a clear solution of the anti-infective and the corticosteroid in a predominantly aqueous phase and a formulation in suspension form causes discomfort to the eye and requires inclusion of many additional excipients to formulate a stable suspension composition which may also cause irritation to the eye.
- a clear solution composition is the most preferred formulation for administration to the eye.
- a stable ophthalmic solution composition may be expected to have better patient compliance and acceptance as compared to the available suspension formulation. Hence it is the object of the present invention to provide a clear, stable ophthalmic solution composition of a combination of an anti-infective agent and an anti- inflammatory steroid.
- United States Patent No. 4,844,902 assigned to Bayer, Germany claims a topically applicable formulation comprising by weight about 0.01 to 30% of an anti-bacterially active compound, 0.01 to 10% of a corticosteroid and a carrier.
- the invention relates to topically applicable formulations for the treatment or prophylaxis of infections, diseases and injuries to the skin, including burns.
- the topical formulations include solutions, sprays, lotions, gels, ointments, creams, powders, dusting powder sprays, pastes, suspensions, emulsions, foams and sticks containing the active compounds.
- the solution compositions exemplified in this patent are not ophthalmic compositions because they use solvents that may be unacceptable for ophthalmic use.
- This patent discloses pharmaceutical compositions containing a quinolone antibiotic, such as ciprofloxacin and a steroid such as rimexolone, dexamethasone, fluorometholone and the like for topical ophthalmic delivery.
- the exemplified compositions are suspension composition and ointment for ophthalmic use, thus this patent does not disclose a clear, stable solution composition of an antibiotic and corticosteroid as provided in the present invention.
- United States Patent No. 6,359,016 assigned to Alcon Universal Ltd. relates to topical suspension formulations containing ciprofloxacin and dexamethasone. Specifically the invention relates to stable suspension formulations of ciprofloxacin and dexamethasone that lack a nonionic tonicity agent, such as glycerol or mannitol. Thus this patent does not provide means of developing a clear, stable solution composition for a combination of an anti-bacterial and an anti-inflammatory agent, which is the most preferred composition for administration to the eye.
- 20010049366 assigned to Alcon Universal Ltd relates to topical solution formulations containing an antibiotic, a corticosteroid and a solubilizing agent and they claim a topically administrable solution composition intended for application to the eye, ear, nose or skin comprising a) 0.01-1% (w/v) of a corticosteroid; b) 0.1-1.5% (w/v) of an antibiotic drug; c) a vitamin E tocopheryl derivative in an amount sufficient to solubilize the corticosteroid; d) a tonicity agent in an amount sufficient to cause the composition to have an osmolality of about 250-350 mOsm; and e) a buffering agent.
- the solubilizing agent in the formulation of the patented invention is a vitamin E tocopherol and the patent does not provide formulations wherein cyclodextrin is used to solubilize the corticosteroid.
- PCT application WO 02/39993 claims a stable pharmaceutical preparation of a combination drug, comprising amongst others of (i) an anti-infective agent, selected from the group consisting of quinolone derivatives, amino-glycoside derivatives and their pharmaceutically acceptable salts; (ii) an ant-inflammatory agent which is a corticosteroid; (iii) a complexation enhancing polymer; (iv) a solubilizer exhibiting an inclusion phenomena; (v) pharmaceutically acceptable excipients within a suitable carrier system.
- an anti-infective agent selected from the group consisting of quinolone derivatives, amino-glycoside derivatives and their pharmaceutically acceptable salts
- an ant-inflammatory agent which is a corticosteroid
- a complexation enhancing polymer e.g., a solubilizer exhibiting an inclusion phenomena
- pharmaceutically acceptable excipients within a suitable carrier system e.g., a solubilizer exhibiting an inclusion phenomena.
- the invention exemplifies an eye drop solution formulation of dexamethasone and ciprofloxacin, wherein beta-cyclodextrin is added as the solubilizer exhibiting an inclusion phenomena and polyvinyl alcohol is added as the complexation-enhancing polymer.
- the patent thus teaches the preparation of solutions of the anti-infective agent and the anti-inflammatory agent with the use of an inclusion complex forming solubilizer in presence of a complexation-enhancing polymer.
- Use of a complexation-enhancing polymer effectively reduces the amount of uncomplexed drug in solution. A higher amount of drug available in the free uncomplexed form would be desirable.
- the objects of the invention are - 1) To provide ophthalmic composition of an anti-infective agent and an anti- inflammatory agent. 2) To provide an ophthalmic composition comprising an anti-infective agent and an anti-inflammatory agent in a liquid vehicle along with other pharmaceutically acceptable excipients.
- the present invention provides a clear, stable ophthalmic composition
- a clear, stable ophthalmic composition comprising (a) an anti-infective agent; (b) an anti-inflammatory agent and (c) a complexing agent capable of forming an inclusion complex.
- the present invention particularly provides a clear, stable ophthalmic composition
- a clear, stable ophthalmic composition comprising (a) an anti-infective agent; (b) a steroidal anti-inflammatory agent; (c) a complexing agent capable of forming an inclusion complex and (d) other pharmaceutically acceptable excipients in a liquid vehicle such that the composition is free of any other complexation enhancing polymer and such composition when stored at room temperature for one year does not show any precipitation over the storage period.
- the said anti-infective agent of the present invention is a quinoline derivative like ciprofloxacin hydrochloride or an aminoglycolide derivative like tobramycin and the anti- inflammatory agent is a corticosteroid like dexamethasone.
- a topically administrable solution formulation containing an anti-infective agent, a steroidal anti-inflammatory agent, a complexing agent capable of forming an inclusion complex and other pharmaceutically acceptable excipients.
- the said actives and excipients are incorporated in a liquid vehicle consisting of water resulting in a clear stable solution for ocular treatment of infection and inflammation.
- the anti-infective agent may be any ophthalmically useful quinolone derivative or an aminoglycoside derivative.
- the quinolone derivative that may preferably be used in the present invention include fluoroquinolones from the group consisting of ciprofloxacin, moxifloxacin, gatifloxacin, gemifloxacin, norfloxacin, ofloxacin, levofloxacin and trovofloxacin, its pharmaceutically acceptable salts and the like and the aminoglycoside derivative may be selected from the group consisting of tobramycin, gentamycin and its pharmaceutically acceptable salts.
- the preferred quinolone anti-infective ingredient of the present invention is ciprofloxacin, a fluoroquinolone anti-infective, active against a broad spectrum of gram-positive and gram-negative ocular pathogens and the preferred form is ciprofloxacin hydrochloride. It is available as the monohydrochloride monohydrate salt of l-cyclopropyl-6-fluro-l,4-dihydro-4-oxo-7-(l-piperazinyl)-3- quinoline-carboxylic acid.
- the preferred aminoglycoside antibacterial anti-infective agent of the present invention is tobramycin, chemically which is O-3-deoxy- ⁇ -D- glucopyranosyl-( 1 -6)-0- [2,6-diamino-2,3 ,6-trideoxy- ⁇ -D-ribo-hexopyranosyl-(l -4)]-2- deoxy-D-streptamine.
- the anti-inflammatory agents that may preferably be used in the present invention selected from a corticosteroid include flurometholone, betamethasone, prednisolone, dexamethasone, their derivatives and the like.
- the preferred corticosteroid ingredient of the present invention is dexamethasone and/or its derivatives.
- Dexamethasone is a synthetic analog of naturally occurring glucocorticoids (hydrocortisone and cortisone). It is available as dexamethasone alcohol, dexamethasone acetate, dexamethasone sodium phosphate and the like.
- the anit-infective agent included in the stable ophthalmic composition of the present invention will comprise about 0.1 to 30% weight/volume units and the steroidal anti- inflammatory agent will comprise about 0.01 to 10% weight/volume units.
- the anti-infective is ciprofloxacin HC1 and the corticosteroid is dexamethasone the amount ranges from 0.1 to 1.5% w/v and 0.01 to 1.0% w/v respectively.
- the stable ophthalmic composition of the present invention comprises a complexing agent capable of solubilizing the steroid in water by forming an inclusion complex.
- the complexing agents selected in the present invention may be a cyclodextrin and its derivatives which can be well tolerated when administered by ophthalmic route for e.g. ⁇ -, ⁇ - or ⁇ - cyclodextrins or derivatives thereof, preferably derivatives wherein one or more of the hydroxy groups are substituted, e.g.
- Substituted cyclodextrins which can be used in the present invention, include ethers, polyethers or mixed ethers thereof.
- substituted cyclodextrins are ethers wherein the hydrogen of one or more cyclodextrin hydroxy groups is replaced by one or more cyclodextrin hydroxy groups is replaced by C 1-3 alkyl, hydroxy-C 2- alkyl or carboxy-C 1-2 alkyl or more particularly by methyl, ethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, carboxymethyl or carboxyethyl.
- Most preferred cyclodextrins used in the present invention are ⁇ -cyclodextrin ethers and polyethers e.g.
- the cyclodextrin is preferably used at 0.05% w/v to about 15.0% w/v, more preferably at 1.0% w/v to about 10.0% w/v and most preferably about 1.5% w/v to about 5.5% w/v.
- hydroxypropyl- ⁇ -cyclodextrin is used.
- Hydroxypropyl- ⁇ -cyclodextrin is made by reacting ⁇ -cyclodextrin with propylene oxide, it has a true density of 1.378 g/cm 3 and has a cavity diameter of 6.0 - 6.5 A.
- cyclodextrin is present in an amount sufficient to solubilize the corticosteroid ingredient.
- complexation enhancing agents consisting of non-ionic polymers has been used in the preparation of cyclodextrin-drug complexes as a means for increasing the solubilizing and stabilizing effects of cyclodextrin derivatives on drugs and complexation therewith.
- a clear and stable solution composition is provided without the inclusion of such additional polymers by a simple process of incorporating the actives and other excipients in a liquid vehicle to obtain a composition which when stored at room temperature for one year does not show any precipitation over the storage period and the active agents are also stabilized against their chemical decomposition.
- stable ophthalmic composition of the present invention may contain other ophthalmically acceptable excipients, e.g. osmogens, chelating agents, preservative agents, buffers etc. present in an amount ranging from 0.01% w/v to about 99.9% w/v.
- osmogens e.g. osmogens, chelating agents, preservative agents, buffers etc. present in an amount ranging from 0.01% w/v to about 99.9% w/v.
- Examples of the osmogent(s) that may be used in the stable ophthalmic composition of the present invention include inorganic salts such as magnesium chloride or magnesium sulfate, lithium, sodium or potassium chloride, lithium, sodium or potassium hydrogen phosphate, lithium, sodium or potassium dihydrogen phosphate, salts of organic acids such as sodium or potassium acetate, magnesium succinate, sodium benzoate, sodium citrate or sodium ascorbate; sodium carbonate or sodium bicarbonate; carbohydrates such as mannitol, sorbitol, arabinose, ribose, xylose, glucose, dextrose, fructose, mannose, galactose, sucrose, maltose, lactose, raffinose, inositol, xylitol, maltitol; water-soluble amino acids such as glycine, leucine, alanine, or methionine; urea and the like, and mixtures thereof.
- chelating agents may be used in the stable ophthalmic composition of the present invention and are selected from a group comprising edetic acid, edetic acid salts like disodium edetate, sodium edetate, edetate calcium disodium and trisodium edetate, malic acid and the like and mixtures thereof. Chelating agents if present is used in an amount from about 0.001 to 0.1% w/v. In preferred embodiments disodium edetate is added at concentration of 0.05% w/v.
- the stable ophthalmic compositions of the present invention may be prepared without a preservative as a "unit-dose" or "unpreserved” formulation or as "preserved” or "multi- dose” formulation.
- the multi-dose compositions may contain an ophthalmically acceptable preservative.
- the preservative agent that may be added in the stable ophthalmic composition of the present invention to protect the solution composition from microbial contamination are selected from the group comprising benzalkonium chloride, methyl paraben, propyl paraben and their salts, potassium sorbate and sodium benzoate.
- the preservative may be present in an amount ranging from about 0.002 to 0.5 % w/w of the formulation.
- the preferred preservative used in the present invention is benzalkonium chloride.
- the stable ophthalmic composition of the present invention may additionally contain ophthalmically acceptable solubilizing agent that solubilize the drug while maintaining its availability in a free uncomplexed form.
- the solubilizer is such that it does not include the drug in an inclusion cavity. Examples of such a solubilizer include cosolvents, complexing agents that form a rapidly dissociating complex, surfactants, and hydrotropic agents.
- the pH of the stable ophthalmic composition of the present invention may be adjusted using suitable pH adjusting agents, selected from a group of buffering agents, comprising lactic acid, citric acid, tartaric acid, phosphoric acid, acetic acid, hydrochloric acid, nitric acid, sodium or potassium metaphosphate, sodium or potassium phosphate, sodium or potassium acetate, ammonia, sodium carbonate, sodium or potassium hydroxide, dibasic sodium phosphate, sodium borate, and the like and mixtures thereof. Adjusting pH using strong mineral acids like hydrochloric acid is more preferred to a pH less than 6.5.
- the stable ophthalmic composition is adjusted to a pH preferably in the range between about 3.5 and 6.0, more preferably between about 4.0 and 5.0 and most preferably between about 4.4 and 4.6.
- the clear, stable solution composition may be administered topically to the eye as well as if desired may be administered to the ear, nose or skin.
- the stable ophthalmic composition of the present invention may be prepared by mixing the two drugs and other pharmaceutically acceptable excipients in purified water.
- the solution pH may be adjusted if necessary. In specific embodiments comprising dexamethasone and ciprofloxacin HCl the pH is about 4.5.
- the solutions thus obtained may be filled in suitable containers such as multidose vials with addition of preservatives or as unit dose vials without a preservative.
- the ophthalmic compositions may be sterilized by any techniques used in art, preferably by filtration.
- the stable ophthalmic composition of the present invention may be prepared by a simple process comprising dissolving mannitol in water for injection, adding hydroxypropyl ⁇ -cyclodextrin in small increments to the above solution and stirring to get a clear solution. Dexamethasone is then added to this solution and stirred to get a clear solution. Ciprofloxacin first and then disodium edetate and benzalkonium chloride solution is added and dissolved to get a clear solution and volume made up with water for injection. The solution may be filtered to obtain a clear stable ophthalmic composition, which is then filled in vials.
- Mannitol is dissolved in water for injection, hydroxypropyl ⁇ -cyclodextrin is added in small increments to this solution and stirred to get a clear solution.
- Dexamethasone is added to this solution and stirred to get a clear solution.
- Ciprofloxacin is then added to the solution and stirred till it is clear.
- Disodium edetate and benzalkonium chloride solution is added and dissolved to get a clear solution. The pH of the solution was 4.5. After making up the volume with water for injection, the solution is filtered and filled in vials.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05008913A MXPA05008913A (en) | 2003-02-21 | 2004-02-23 | Stable ophthalmic formulation containing an antibiotic and a corticosteroid. |
EP04745101A EP1596823A2 (en) | 2003-02-21 | 2004-02-23 | A stable ophthalmic composition |
JP2006507625A JP2006518769A (en) | 2003-02-21 | 2004-02-23 | Stable ophthalmic composition |
US10/546,417 US20070148192A1 (en) | 2003-02-21 | 2004-02-23 | Stable ophthalmic composition |
CA002516429A CA2516429A1 (en) | 2003-02-21 | 2004-02-23 | Stable ophthalmic formulation containing an antibiotic and a corticosteroid |
BRPI0407583-8A BRPI0407583A (en) | 2003-02-21 | 2004-02-23 | clearly and stable ophthalmic solution |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN212MU2003 | 2003-02-21 | ||
IN212/MUM/2003 | 2003-02-21 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2004087043A2 true WO2004087043A2 (en) | 2004-10-14 |
WO2004087043A3 WO2004087043A3 (en) | 2004-12-16 |
WO2004087043B1 WO2004087043B1 (en) | 2005-01-27 |
Family
ID=33104995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2004/000048 WO2004087043A2 (en) | 2003-02-21 | 2004-02-23 | Stable ophthalmic formulation containing an antibiotic and a corticosteroid |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070148192A1 (en) |
EP (1) | EP1596823A2 (en) |
JP (1) | JP2006518769A (en) |
KR (1) | KR20050105477A (en) |
BR (1) | BRPI0407583A (en) |
CA (1) | CA2516429A1 (en) |
MX (1) | MXPA05008913A (en) |
WO (1) | WO2004087043A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006043965A1 (en) * | 2004-10-14 | 2006-04-27 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
WO2007011874A2 (en) * | 2005-07-15 | 2007-01-25 | Chakshu Research Inc. | Formulation and method for administration of ophthalmologically active agents |
WO2007099431A2 (en) * | 2006-02-28 | 2007-09-07 | Wockhardt Ltd | An aqueous liquid pharmaceutical compositions of gatifloxacin |
WO2008002117A1 (en) * | 2006-06-27 | 2008-01-03 | Jimenez Bayardo, Arturo | Ophthalmic solution of ciprofloxacin and dexamethasone |
JP2009530275A (en) * | 2006-03-14 | 2009-08-27 | シーエルエス・ファーマシューティカルス,インコーポレーテッド | Ophthalmic composition containing povidone iodine |
US20100009979A1 (en) * | 2006-03-08 | 2010-01-14 | Bayer Animal Health Gmbh | Pharmaceuticals containing fluoroquinolones |
US20110117189A1 (en) * | 2008-07-08 | 2011-05-19 | S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. | Ophthalmic compositions for treating pathologies of the posterior segment of the eye |
EP2502616A1 (en) * | 2011-03-21 | 2012-09-26 | Matthew Krayenbuhl | Pharmaceutical nasal composition |
US8569272B2 (en) | 2003-11-12 | 2013-10-29 | Allergan, Inc. | Methods for treating a posterior segment of an eye |
US20140162990A1 (en) * | 2012-12-06 | 2014-06-12 | Alcon Research, Ltd. | Finafloxacin suspension compositions |
US8846094B2 (en) | 2003-11-12 | 2014-09-30 | Allergan, Inc. | Peripherally administered viscous formulations |
US9039761B2 (en) | 2006-08-04 | 2015-05-26 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
US9149525B2 (en) | 2008-02-25 | 2015-10-06 | Eyegate Pharmaceuticals, Inc. | Delivery of corticosteroids through iontophoresis |
US9827324B2 (en) | 2003-12-31 | 2017-11-28 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
AU2016253668B2 (en) * | 2006-03-14 | 2018-12-06 | Cls Pharmaceuticals, Inc. | Ophthalmic compositions comprising povidone-iodine |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5310590A (en) * | 1993-02-04 | 1994-05-10 | Minnesota Mining And Manufacturing Company | Stitchbonded articles |
US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
CA2553381C (en) | 2004-01-20 | 2011-03-22 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
ES2493641T3 (en) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Nasal administration of aqueous corticosteroid solutions |
CN106038481A (en) * | 2007-06-28 | 2016-10-26 | 锡德克斯药物公司 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
KR101304341B1 (en) * | 2011-09-19 | 2013-09-11 | 한미약품 주식회사 | PHARMACEUTICAL COMPOSITION COMPRISING CORTICOSTEROID, ANTIHISTAMINIC AGENT AND β-CYCLODEXTRIN WITH IMPROVED STABILITY |
US20150164882A1 (en) | 2013-07-22 | 2015-06-18 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
US20160279055A1 (en) | 2013-07-22 | 2016-09-29 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof |
KR20190109604A (en) * | 2016-05-06 | 2019-09-25 | 해로우 헬스 인코포레이티드 | Pharmaceutical ophthalmic compositions and methods for fabricating thereof |
HRP20220046T1 (en) * | 2016-11-29 | 2022-04-15 | Oculis SA | Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery |
CN113490691A (en) | 2019-01-03 | 2021-10-08 | 劣势者药物有限公司 | Cyclodextrin dimers, compositions thereof, and uses thereof |
US20230233572A1 (en) * | 2020-06-11 | 2023-07-27 | Sentiss Pharma Private Limited | Ophthalmic compositions comprising a combination of fluoroquinolone antibacterial agent and an anti-inflammatory agent |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990001933A1 (en) * | 1988-08-26 | 1990-03-08 | Alcon Laboratories, Inc. | Combination of quinolone antibiotics and steroids for topical ophthalmic use |
US20010049366A1 (en) * | 2000-02-09 | 2001-12-06 | Alcon Universal Ltd. | Topical solution formulations containing an antibiotic and a corticosteroid |
WO2002039993A2 (en) * | 2000-11-15 | 2002-05-23 | Chandavarkar Mohan A | Pharmaceutival preparations comprising corticosteroids and antiinfective agents |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3704907A1 (en) * | 1987-02-17 | 1988-08-25 | Bayer Ag | TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS |
US5422116A (en) * | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
ATE252887T1 (en) * | 1999-09-24 | 2003-11-15 | Alcon Inc | TOPICAL SUSPENSION FORMULATIONS CONTAINING CIPROFLOXACIN AND DEXAMETHASON |
-
2004
- 2004-02-23 MX MXPA05008913A patent/MXPA05008913A/en unknown
- 2004-02-23 EP EP04745101A patent/EP1596823A2/en not_active Withdrawn
- 2004-02-23 KR KR1020057015370A patent/KR20050105477A/en not_active Application Discontinuation
- 2004-02-23 BR BRPI0407583-8A patent/BRPI0407583A/en not_active IP Right Cessation
- 2004-02-23 CA CA002516429A patent/CA2516429A1/en not_active Abandoned
- 2004-02-23 US US10/546,417 patent/US20070148192A1/en not_active Abandoned
- 2004-02-23 WO PCT/IN2004/000048 patent/WO2004087043A2/en active Application Filing
- 2004-02-23 JP JP2006507625A patent/JP2006518769A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990001933A1 (en) * | 1988-08-26 | 1990-03-08 | Alcon Laboratories, Inc. | Combination of quinolone antibiotics and steroids for topical ophthalmic use |
US20010049366A1 (en) * | 2000-02-09 | 2001-12-06 | Alcon Universal Ltd. | Topical solution formulations containing an antibiotic and a corticosteroid |
WO2002039993A2 (en) * | 2000-11-15 | 2002-05-23 | Chandavarkar Mohan A | Pharmaceutival preparations comprising corticosteroids and antiinfective agents |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8846094B2 (en) | 2003-11-12 | 2014-09-30 | Allergan, Inc. | Peripherally administered viscous formulations |
US9089478B2 (en) | 2003-11-12 | 2015-07-28 | Allergen, Inc. | Peripherally administered viscous formulations |
US8569272B2 (en) | 2003-11-12 | 2013-10-29 | Allergan, Inc. | Methods for treating a posterior segment of an eye |
US10159752B2 (en) | 2003-12-31 | 2018-12-25 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US10207008B2 (en) | 2003-12-31 | 2019-02-19 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US10799599B2 (en) | 2003-12-31 | 2020-10-13 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US9827324B2 (en) | 2003-12-31 | 2017-11-28 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
WO2006043965A1 (en) * | 2004-10-14 | 2006-04-27 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
WO2007011874A3 (en) * | 2005-07-15 | 2008-04-24 | Chakshu Res Inc | Formulation and method for administration of ophthalmologically active agents |
WO2007011874A2 (en) * | 2005-07-15 | 2007-01-25 | Chakshu Research Inc. | Formulation and method for administration of ophthalmologically active agents |
WO2007099431A3 (en) * | 2006-02-28 | 2008-02-07 | Wockhardt Ltd | An aqueous liquid pharmaceutical compositions of gatifloxacin |
WO2007099431A2 (en) * | 2006-02-28 | 2007-09-07 | Wockhardt Ltd | An aqueous liquid pharmaceutical compositions of gatifloxacin |
US10231925B2 (en) * | 2006-03-08 | 2019-03-19 | Bayer Intellectual Property Gmbh | Pharmaceuticals containing fluoroquinolones |
US20100009979A1 (en) * | 2006-03-08 | 2010-01-14 | Bayer Animal Health Gmbh | Pharmaceuticals containing fluoroquinolones |
TWI494105B (en) * | 2006-03-08 | 2015-08-01 | Bayer Ip Gmbh | Pharmaceuticals containing fluoroquinolones |
US9855295B2 (en) | 2006-03-14 | 2018-01-02 | Clarus Cls Holdings, Llc | Methods of using ophthalmic compositions comprising povidone-iodine |
JP2013136612A (en) * | 2006-03-14 | 2013-07-11 | Cls Pharmaceuticals Inc | Ophthalmic composition comprising povidone-iodine |
US10849928B2 (en) | 2006-03-14 | 2020-12-01 | Clarus Cls Holdings, Llc | Methods of using ophthalmic compositions comprising povidone-iodine |
US8765724B2 (en) | 2006-03-14 | 2014-07-01 | Cls Pharmaceuticals, Inc. | Methods of using ophthalmic compositions comprising povidone-iodine |
KR102116723B1 (en) | 2006-03-14 | 2020-06-01 | 씨엘에스 파머수티컬스, 인크. | Ophthalmic compositions comprising povidone-iodine |
KR102044600B1 (en) | 2006-03-14 | 2019-11-13 | 씨엘에스 파머수티컬스, 인크. | Ophthalmic compositions comprising povidone-iodine |
KR20160122276A (en) * | 2006-03-14 | 2016-10-21 | 씨엘에스 파머수티컬스, 인크. | Ophthalmic compositions comprising povidone-iodine |
KR20190031345A (en) * | 2006-03-14 | 2019-03-25 | 씨엘에스 파머수티컬스, 인크. | Ophthalmic compositions comprising povidone-iodine |
JP2016216481A (en) * | 2006-03-14 | 2016-12-22 | シーエルエス・ファーマシューティカルス,インコーポレーテッド | Ophthalmic compositions comprising povidone-iodine |
JP2009530275A (en) * | 2006-03-14 | 2009-08-27 | シーエルエス・ファーマシューティカルス,インコーポレーテッド | Ophthalmic composition containing povidone iodine |
AU2016253668B2 (en) * | 2006-03-14 | 2018-12-06 | Cls Pharmaceuticals, Inc. | Ophthalmic compositions comprising povidone-iodine |
EP2772258A1 (en) * | 2006-03-14 | 2014-09-03 | CLS Pharmaceuticals, Inc. | Ophthalmic compositions comprising povidone-iodine |
JP2018039829A (en) * | 2006-03-14 | 2018-03-15 | シーエルエス・ファーマシューティカルス,インコーポレーテッド | Ophthalmic compositions comprising povidone iodine |
WO2008002117A1 (en) * | 2006-06-27 | 2008-01-03 | Jimenez Bayardo, Arturo | Ophthalmic solution of ciprofloxacin and dexamethasone |
US9039761B2 (en) | 2006-08-04 | 2015-05-26 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
US9820935B2 (en) | 2008-02-25 | 2017-11-21 | Eyegate Pharmaceuticals, Inc. | Delivery of corticosteroids through iontophoresis |
US10376463B2 (en) | 2008-02-25 | 2019-08-13 | Eyegate Pharmaceuticals, Inc. | Ocular iontophoretic delivery of dexamethasone and formulations thereof |
US9149525B2 (en) | 2008-02-25 | 2015-10-06 | Eyegate Pharmaceuticals, Inc. | Delivery of corticosteroids through iontophoresis |
US20110117189A1 (en) * | 2008-07-08 | 2011-05-19 | S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. | Ophthalmic compositions for treating pathologies of the posterior segment of the eye |
WO2012127407A1 (en) * | 2011-03-21 | 2012-09-27 | Dos Santos, Antonio | Pharmaceutical composition for use in nasal administration containing corticoid, and a quinolone or fusidic acid |
EP2502616A1 (en) * | 2011-03-21 | 2012-09-26 | Matthew Krayenbuhl | Pharmaceutical nasal composition |
US9636350B2 (en) | 2011-03-21 | 2017-05-02 | Matthew Krayenbuhl | Pharmaceutical composition for use in nasal administration containing corticoid, and a quinolone or fusidic acid |
US9504691B2 (en) * | 2012-12-06 | 2016-11-29 | Alcon Research, Ltd. | Finafloxacin suspension compositions |
US20140162990A1 (en) * | 2012-12-06 | 2014-06-12 | Alcon Research, Ltd. | Finafloxacin suspension compositions |
Also Published As
Publication number | Publication date |
---|---|
CA2516429A1 (en) | 2004-10-14 |
WO2004087043A3 (en) | 2004-12-16 |
KR20050105477A (en) | 2005-11-04 |
JP2006518769A (en) | 2006-08-17 |
US20070148192A1 (en) | 2007-06-28 |
MXPA05008913A (en) | 2005-10-05 |
BRPI0407583A (en) | 2006-02-14 |
EP1596823A2 (en) | 2005-11-23 |
WO2004087043B1 (en) | 2005-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070148192A1 (en) | Stable ophthalmic composition | |
EP0986403B1 (en) | Composition with extended shelf-life storage comprising cyclodextrin and drugs or prodrugs that decompose to water-insoluble components | |
US20070248565A1 (en) | Pharmaceutical preparations comprising corticosteroids and antiinfective agents | |
EP2709610B1 (en) | High concentration olopatadine ophthalmic composition | |
SK279503B6 (en) | Antiallergic composition for ophthalmic or nasal use | |
EP2427214B1 (en) | Topical solution formulations containing a corticosteroid and a cyclodextrin | |
AU2002216357A1 (en) | Pharmaceutival preparations comprising corticosteroids and antiinfective agents | |
US20060193783A1 (en) | Low dose corticosteroid composition | |
WO2004069280A1 (en) | Pharmaceutical inclusion complexes containing a steroid and optionally an antibacterial agent | |
JP3781792B2 (en) | Ophthalmic suspension containing difluprednate | |
WO2014135123A1 (en) | 17α-ethynyl-androst-5-ene-3β,7β,17β-triol ophthalmic preparation | |
EP2994109B1 (en) | Aqueous ophthalmic formulations based on azithromycin | |
US20230181555A1 (en) | Stable and preserved pharmaceutical compositions of bilastine | |
CA2554908A1 (en) | Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration | |
KR102421758B1 (en) | Ophthalmic Composition | |
EP3911364B1 (en) | Chemically and physically stable topical ophthalmic nepafenac-based formulations | |
ZA200506549B (en) | A low dose corticosteroid composition | |
EP3641764A1 (en) | Tropicamide-based ophthalmic formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
B | Later publication of amended claims |
Effective date: 20041123 |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2516429 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057015370 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/008913 Country of ref document: MX Ref document number: 2006507625 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004745101 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057015370 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004745101 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0407583 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007148192 Country of ref document: US Ref document number: 10546417 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10546417 Country of ref document: US |